Keyphrases
Atrial Fibrillation
100%
Stroke Prevention
41%
Non-valvular Atrial Fibrillation
33%
Direct Oral Anticoagulants
29%
Acute Coronary Artery Disease
27%
Rivaroxaban
27%
Spain
27%
Risk Factors
22%
Warfarin
22%
Vitamin K Antagonists
21%
Dabigatran
20%
Disease-associated
18%
Cardiology
17%
Anticoagulation
16%
Heart Failure
16%
F12 Gene
13%
Diabetic Patients
13%
Epidemiology
13%
Spanish Population
13%
Systemic Thromboembolism
13%
RE-LY
13%
Homozygosity
13%
Assistance Model
13%
First Visit
13%
Cardiologists
13%
Elderly Patients
13%
Polymorphism
13%
Cardiovascular Disease
13%
Type 1 Diabetes Mellitus (T1DM)
13%
T Allele
13%
European Heart Rhythm Association
13%
Association Score
13%
New Evidence
13%
Multiple Comorbidities
13%
Plasma Parameters
13%
Cost-effectiveness
13%
Cardioversion
13%
Anticoagulant Therapy
13%
Anemia
13%
Primary Care
13%
Echocardiographic
13%
Patient Management
13%
Function Maintenance
13%
Sinus Rhythm
13%
Functional Class
13%
Ischemic Heart Disease
13%
Thrombin-activatable Fibrinolysis Inhibitor
13%
Iron Deficiency
13%
Prescription Pattern
13%
Antithrombotic Therapy
13%
Medicine and Dentistry
Atrial Fibrillation
68%
Direct Oral Anticoagulant
27%
Antithrombotic
24%
Thromboembolism
21%
Cardiology
20%
Vitamin K Antagonist
17%
Comorbidity
15%
Anemia
13%
Iron Deficiency
13%
Diabetes Mellitus
13%
Cardiovascular Disease
13%
Cohort Effect
13%
Ischemic Heart Disease
13%
Primary Health Care
13%
Anticoagulation
13%
Elderly Patient
13%
Rivaroxaban
13%
Congestive Heart Failure
13%
Brain Ischemia
13%
Apoplexy
11%
Cardiac Dysrhythmia
9%
Clinical Trial
6%
Revascularization
5%
Diabetes
5%
Pharmacology, Toxicology and Pharmaceutical Science
Atrial Fibrillation
82%
Cerebrovascular Accident
50%
Thromboembolism
32%
Rivaroxaban
27%
Anticoagulant Agent
22%
Warfarin
22%
Antivitamin K
21%
Dabigatran
20%
Direct Oral Anticoagulant
18%
Thrombin Activatable Fibrinolysis Inhibitor
13%
Coronary Artery Disease
13%
Diabetes Mellitus
13%
Cardiovascular Disease
13%
Comorbidity
13%
Clinical Trial
12%
Bleeding
10%
Anticoagulation Therapy
6%